<DOC>
	<DOCNO>NCT01879748</DOCNO>
	<brief_summary>This study design evaluate pharmacokinetics rasagiline healthy Japanese Caucasian subject single multiple dos rasagiline .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics , Safety , Tolerability Single Multiple Doses Rasagiline</brief_title>
	<detailed_description>This single-center , double-blind , placebo-controlled , randomize study healthy Japanese Caucasian subject administration single multiple dos rasagiline . All subject screen visit within 28 day check-in day ( day -1 ) confirm eligibility . Eligible subject admit investigational center study day -1 eligibility participate study confirm . On morning day 1 , subject randomly assign receive daily dose 0.5 , 1 , 2 mg rasagiline placebo time every morning overnight fast ( least 10 hour ) day 1 10 . Venous blood sample ( 4 mL ) pharmacokinetic analysis collect specified time point 24 hour study drug administration day 1 48 hour study drug administration day 10 . The duration study participation subject approximately 6 week .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>1 . The subject able read , speak , write English Japanese , applicable . 2 . The subject able understand willing comply study requirement ( eg , dietary , exercise , tobacco , alcohol restriction ) provide write informed consent participate study . 3 . The subject man woman , 20 50 year age , inclusive . 4 . The subject body mass index ( BMI ) 18.028.0 kg/m2 , inclusive . 5 . The subject good health , determine medical history , ECG , vital sign , physical examination , clinical laboratory test . 6 . If female childbearing potential , subject must negative Î²hCG test screen negative urine human chorionic gonadotropin ( HCG ) test checkin willing able use one follow medically acceptable double barrier method birth control screen visit endofstudy visit : nonhormonal intrauterine device condom , diaphragm condom , condom spermicide . Female subject postmenopausal ( 1 year since last menses ) must elevate follicle stimulate hormone ( FSH ) level 35 U/L , surgically sterile . 7 . The subject must complete screen process within 4 week study drug administration . 8 . The subject must willing able comply study restriction remain clinic require duration study period , willing return clinic followup evaluation , specify protocol . Additional inclusion criterion Japanese subject : 9 . The subject born Japan hold valid Japanese passport . 10 . The subject 2 Japanese parent 4 Japanese grandparent , confirm interview . 11 . The subject living outside Japan 10 year few confirm interview . Additional inclusion criterion Caucasian subject : 12 . The subject parent grandparent Japanese descent confirm interview . 1 . The subject woman pregnant lactating . 2 . The subject significant food drug allergy know allergy sensitivity rasagiline derivative formulation excipients . 3 . The subject unwilling refrain vigorous exercise ( eg , strenuous unaccustomed weight lifting , run , bicycling , etc ) 7 day first day study drug administration final assessment . 4 . The subject 1 follow condition note amount time screen time screen first day study drug administration : major trauma surgery last 2 month acute infection last 2 week malignancy within last 5 year 5 . The subject history tuberculosis . 6 . The subject condition may interfere drug absorption , distribution , metabolism , excretion . 7 . The subject suffering , clinically significant history , 1 following : cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological , immunological , psychiatric disorder ( ) , history illness , opinion investigator , might confound result study pose additional risk subject participate study . 8 . The subject positive test hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody . 9 . The subject history hypertension occasional increase blood pressure , history vascular structural abnormality . 10 . The subject sit blood pressure outside range 80 139 mm Hg ( systolic ) 45 89 mm Hg ( diastolic ) ( least 5minute rest ) measure screen . Blood pressure may retested twice interval 5 minute . The blood pressure consider sustain either systolic diastolic pressure exceed state limit 3 assessment . 11 . The subject use 1 follow prohibit drug food : investigational drug ( new chemical entity ) month prior first day study drug administration antidepressant , include selective serotonin reuptake inhibitor , tricyclic tetracyclic antidepressant , within 42 day first day study drug administration MAO inhibitor , include reserpine methyldopa , within 3 month prior first day study drug administration medication ( include overthecounter [ OTC ] medication , vitamin , herbal nutritional supplement ) within 14 day first day study drug administration ( except paracetamol/acetaminophen ibuprofen use occasionally , 24 hour first day study drug administration ) drug know significantly inhibit CYP1A enzyme drug metabolism within 14 day first day study drug administration drug know significantly induce human cytochrome P enzyme ( CYP ) 1A drug metabolism within 28 day first day study drug administration excessive amount alcohol , define 3 drink alcoholic beverage ( eg , beer , wine , distilled spirit ) per day last 3 month first day study drug administration history alcohol abuse excessive amount ( equivalent 6 cup brew coffee per day ) coffee , tea , cola , caffeinated beverage 3 month first day study drug administration grapefruit , Seville oranges , pomelo , product make within 14 day first day study drug administration last day pharmacokinetic sampling . Other exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Azilect</keyword>
	<keyword>rasagiline mesylate</keyword>
</DOC>